Sweden’s Spago Nanomedical will ask shareholders on Nov. 19 to approve delisting from Nasdaq First North, arguing that its listing obstructs financing on acceptable terms for Phase 2a development of its Tumorad radiopharmaceutical in head and neck cancer.
Van Overeem Nuclear BV